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Background: Pain is the most prominent non-motor symptom observed in patients with Parkinson’s disease
(PD). However, the mechanisms underlying the generation of pain in PD have not been well studied. We used a
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD to analyze the relationship
between pain sensory abnormalities and the degeneration of dopaminergic neurons.
Results: The latency to fall off the rotarod and the total distance traveled in round chamber were significantly
reduced in MPTP-induced PD mice, consistent with motor dysfunction. MPTP-treated mice also showed
remarkably shorter nociceptive response latencies compared to saline-treated mice and the subcutaneous
injection of L-3,4-dihydroxyphenylalanine (L-DOPA) partially reversed pain hypersensitivity induced by MPTP
treatment. We found that degeneration of cell bodies and fibers in the substantia nigra pars compacta and the
striatum of MPTP-treated mice. In addition, astrocytic and microglial activation was seen in the subthalamic
nucleus and neuronal activity was significantly increased in the striatum and globus pallidus. However, we did
not observe any changes in neurons, astrocytes, and microglia of both the dorsal and ventral horns in the spinal
cord after MPTP treatment.
Conclusions: These results suggest that the dopaminergic nigrostriatal pathway may have a role in inhibiting
noxious stimuli, and that abnormal inflammatory responses and neural activity in basal ganglia is correlated to
pain processing in PD induced by MPTP treatment.
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Parkinson’s disease (PD) is one of the best examples of a
neurodegenerative disease which manifests comorbid
pain. About 40-60 % of patients with PD experience
various types of acute or chronic pain [1]. To date, these
types of pain have been well characterized in human PD
patients [2], although the exact mechanism of pain* Correspondence: kaang@snu.ac.kr; irislkm@knu.ac.kr
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unless otherwise stated.perception in PD is still elusive. In addition, there are no
apparent remedies to cure PD-induced pain in the field
of clinical neurology. For this reason, it is necessary to
define the pathophysiology in rodent models of PD.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
is a neurotoxin discovered in 1982 and has been widely
used to establish an animal model of PD. We chose
MPTP among the various dopaminergic neurotoxins in-
cluding 6-hydroxydopamine (6-OHDA) and rotenone to
generate a PD model since this compound has specific
advantages: 1) MPTP is known as the only neurotoxin
which causes degeneration of dopaminergic neurons in
humans diagnosed with PD, 2) the administration of
MPTP does not require technical skills or a particularis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of cell bodies and fibers in the substantia nigra pars
compacta (SNpc) and in the striatum [3].
Dopamine receptors (D1 and D2) in the striatum are
involved in nociception [4], and therefore there have
been many studies to assess the alterations of nocicep-
tive sensitivity in rodent PD models [5, 6]. However,
none of these revealed how MPTP affects the sensitivity,
with or without pain induction, of mechanical and ther-
mal nociception in mice. In this study, we found that the
alterations of mechanical and thermal nociceptive
thresholds due to depletion of dopaminergic neurons
and fibers in MPTP-induced PD model mice. We also
investigated that an acute MPTP-induced PD mouse is
an appropriate model to study the mechanism of pain
symptoms in PD.
Although many drugs have been used for treatment of
PD patients, L-DOPA has thus far proven to be the most
effective medication to alleviate motor dysfunction in
PD and antinociceptive effects of L-DOPA has been also
investigated [7]. However, it has been well known that
long-term medication of L-DOPA is highly accompan-
ied by several complications such as disabling fluctua-
tions and dyskinesias [8] overwhelming its therapeutic
benefits.
High frequency deep brain stimulation (DBS) of sub-
thalamic nucleus (STN) (STN-DBS) has been considered
as a powerful therapeutic tool to treat severe motor
symptoms of PD [9] by controlling neural circuitry
forming functional loop within the basal ganglia includ-
ing striatum, globus pallidu (GP), and STN. Recently,
several clinical studies have demonstrated that STN-DBS
could be effective on pain perception in PD patients [10,
11] although the mechanism underlying the therapeutic
effect of STN-DBS on pain modulation remains unrav-
eled yet. In this study, we hypothesized that dysfunction
of neural circuitry via inflammatory responses and ab-
normal neural activity within basal ganglia could be im-
plicated in pain processing. Thus, the aim of this study
was to explore and compare the inflammatory changes
and neural activity in basal ganglia of PD animal model
induced by MPTP treatment.
Results
Acute administration of MPTP induces depletion of
dopaminergic neurons in mice
In the current experiment, an acute MPTP administra-
tion protocol [3] was applied to generate Parkinson’s
disease (PD) model mice. We first confirmed this PD
model by western blot and immunohistochemistry. The
protein level of tyrosine hydroxylase (TH) was reduced
in the striatum and the substantia nigra pars compacta
(SNpc) of MPTP-treated animals compared to saline-
treated animals (Fig. 1a, b). Acute MPTP administrationalso caused the dramatic degeneration of nerve fibers in the
striatum (Fig. 1c, d) and dopaminergic neurons in the SNpc
(Fig. 1e, f ). There was substantial difference in the
fluorescent intensity of TH-immunoreactive fibers in the
dorsal striatum between saline- and MPTP-treated groups
and the magnitude of decrease in the TH-immunoreactive
intensity was much larger in the dorsomedial (DM) striatum
than the dorsolateral (DL) striatum in MPTP-treated
group (Fig. 1c, d). The number of TH-immunoreactive
neurons in the SNpc was significantly decreased in
MPTP-treated group (Fig. 1e, f ). Thus, consistent with the
previous report [3], acute administration of MPTP
significantly reduced dopaminergic neurons in the SNpc
and nerve fibers in the striatum in mice.
MPTP-induced PD model mice exhibit motor deficits
Since the main symptoms of PD are motor deficits [12],
we performed the rotarod test, round chamber test, and
open field test (OFT), which are commonly used to con-
firm the phenotypes of PD model animals [13]. Motor
performance assessed by rotarod test was significantly
decreased after acute MPTP administration (20 mg/kg, 4
times 2 h interval) (Fig. 2a). During the training days,
no difference was observed in the rotarod performance
between saline- and MPTP-treated mice. Saline-treated
mice showed increased rotarod performance on the test
day, whereas MPTP-treated mice showed significantly
decreased falling latency on the rotarod (Fig. 2a). More-
over, a severe motor deficit in MPTP-treated mice was
observed in the round chamber test (Fig. 2b). However,
there were no differences in distance traveled or time
spent in the center between saline- and MPTP-treated
groups in the OFT (Fig. 2c, d), which was consistent
with a previous report that acute MPTP administration
induced no alteration in mobility in the OFT [14], sug-
gesting no changes in basal anxiety levels of the MPTP-
induced PD model mice. Taken together, these results
indicate that the acute MPTP administration protocol
we used induces motor deficits, a behavioral phenotype
of PD model mice.
Administration of MPTP significantly reduces the basal
threshold of nociceptive sensitivity in mice
Next, we used several nociceptive behavioral tests to
measure the nociceptive thresholds of mechanical and
thermal stimulation in saline- and MPTP-treated mice.
The threshold of basal nociceptive response to mechan-
ical stimulation was reduced in the MPTP-treated group
compared to control group in the von Frey test (Fig. 3a).
Next, the threshold of basal nociceptive response to
thermal stimulation on both the 48 °C and 53 °C hot
plate was considerably decreased in the MPTP-treated
group (Fig. 3b). In addition, the MPTP-treated group
also showed significantly reduced tail flick latency
Fig. 1 Depletion of dopaminergic neurons both in the striatum and substantia nigra (SN) induced by MPTP injection in mice. a A representative
western blot image using a tyrosine hydroxylase (TH) antibody. b Quantification of normalized TH expression levels in the striatum and the substantia
nigra pars compacta (SNpc) (n = 5 per group, p < 0.0001, striatum; p < 0.0005, SNpc, unpaired Student’s t-test). c Visualization of loss of dopaminergic
neurons by TH immunostaining in the striatum. d Quantification of reduction of striatal fibers in MPTP-treated mice assessed by TH immunostained
optical density (n = 3 per group, p < 0.05, dorsomedial (DM) or dorsal striatum (SUM), unpaired Student’s t-test; p < 0.05, dorsolateral versus dorsomedial
striatum in saline-treated mice, paired Student’s t-test; p < 0.005, dorsolateral versus dorsomedial striatum in MPTP-treated mice, paired Student’s t-test).
e Visualization of loss of dopaminergic neurons by TH staining in the SNpc. f Quantification of reduction of SNpc dopaminergic neurons in MPTP-treated
mice (n= 3 per group, p< 0.05, unpaired Student’s t-test). DM, Dorsomedial striatum; DL, Dorsolateral striatum
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these results suggest that administration of MPTP with
acute protocol to mice reduces basal nociceptive thresh-
olds to mechanical and thermal stimuli.
We then performed the restoration experiments with
L-DOPA to verify whether nigrostriatal dopaminergicpathway is implicated in pain processing. To examine
whether L-DOPA could ameliorate MPTP-induced hyper-
algesia, L-DOPA (40 mg/kg) or saline was subcutaneously
injected 45 min prior to each experiment. The motor dys-
function in MPTP-treated mice was fully abrogated by
L-DOPA administration (Fig. 3d). The L-DOPA-injected
Fig. 2 Locomotor activity of MPTP-induced PD model mice. a Motor performance of MPTP-treated mice was significantly decreased compared to
saline-treated mice in the rotarod test (n = 15 per group, interaction p < 0.0001; post-hoc p < 0.05, two-way ANOVA). b A severe locomotor deficit
was observed in MPTP-treated mice group (n = 8 of saline and n = 7 of MPTP group, p < 0.0001, unpaired Student’s t-test). c and (d) Saline- and
MPTP-treated mice showed no difference in the open field test (OFT) (n = 4 per group)
Fig. 3 Changes in baseline threshold of nociceptive sensitivity to mechanical and thermal stimulation in MPTP-induced PD model mice and
L-DOPA-treated PD model mice. a Hindpaw withdrawal latency of MPTP-treated mice was significantly reduced in the von Frey test (n = 15
per group, p < 0.001, unpaired Student’s t-test). b The thermal nociceptive response to constant thermal stimulation was increased in MPTP-treated
group in the hot plate test (n = 15 per group, p < 0.005, 48 °C; p < 0.05, 53 °C, unpaired Student’s t-test). c The nociceptive responses to laser heat
stimulation of the tail was increased in MPTP-treated mice (n = 16 for saline- and n = 14 for MPTP-treated group, p < 0.0001, unpaired Student’s t-test).
d Motor dysfunction was eliminated in PD model mice by subcutaneous injection of L-DOPA in the rotarod test (n = 10 for saline and n = 9 for
L-DOPA group, p < 0.001, two-way ANOVA). e In the von Frey test, MPTP-induced hyperalgesia to mechanical stimuli was ameliorated by
subcutaneous injection of L-DOPA (n = 10 for saline and n = 9 for L-DOPA group, p < 0.05, unpaired Student’s t-test). f and (g) Subcutaneous
injection of L-DOPA did not ameliorate MPTP-induced thermal hyperalgesia in the hot plate and the tail flick tests (n = 10 for saline and n = 9
for L-DOPA group)
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in the von Frey test compared to saline-injected PD model
group (Fig. 3e). However, no antinociceptive effect of
L-DOPA was observed in the hot plate test and the tail
flick test (Fig. 3f, g respectively). These results suggest
that the effects of MPTP on nociceptive behaviors were
partially abrogated in mechanical allodynia by L-DOPA
and dopaminergic pathway is related to pain processing,
primarily mechanical allodynia in PD.
MPTP-induced PD model mice show differential
inflammatory responses and neuronal activity in the
brain and spinal cord
Astrocytes are significantly activated by brain injury or
abnormal microenvironment of neural tissues and subse-
quent deleterious impacts on neurons, which may result
in pathological process of the brain, such as neuropathic
pain and neurodegenerative diseases [15]. This reactive
astrogliosis is involved in molecular and morphological
alterations of the astrocytes such as enhancement of
GFAP expression and accumulation of α–synuclein [16].
We next searched for astrocyte activation in the basal
ganglia subunits such as the globus pallidus (GP) and
subthalamic nucleus (STN), which have shown astroglio-
sis after SNpc lesion by injection of 6-OHDA into the
striatum [17]. As shown in other studies [16–18], we
found a strong upregulation of GFAP immunoreactivity
in the STN after MPTP treatment (Fig. 4ae-ah) com-
pared to saline treatment (Fig. 4aa-ad). However, it
was difficult to find astrocytic activation in the caudate-
putamen (CPu) (data not shown) or GP (Fig. 4b) after
acute MPTP treatment, although the astrocytes of the
GP showed more numerous processes and a more
branched appearance (Fig. 4be-bh) compared to those
of saline-treated mice (Fig. 4ba-bd). Many studies on
the mechanisms of pain in PD have concentrated on the
crosstalk between astrocytes and neurons. Astrogliosis is
a main feature of PD to lead neuronal death [19, 20]. To
verify the reciprocal regulation of astrocytes to neurons,
we checked the neuronal changes using NeuN immuno-
labeling in the basal ganglia. We found that acute MPTP
treatment did not involve the neuronal changes in both
STN (Fig. 4af ) and GP (Fig. 4bf ) compared with saline
treatment (Fig. 4ab, 4bb, respectively).
We then examined the microglial activation to confirm
the inflammatory responses to MPTP treatment and we
also found Iba 1-immunopositive microglial activation in
the STN (Fig. 4cc, 4cf ), but not in GP (Fig. 4cb, 4ce)
compared to saline treatment. However, in contrast to
GFAP expression, we could observe the increase of
microglial activation to show inflammatory responses in
the CPu (Fig. 4ca, 4cd) after acute MPTP treatment.
To address whether the dysfunction of SNpc induced by
acute MPTP injection affect an interactive circuitrybetween the basal ganglia subunits, we then investigated
the change of neuronal activity in the basal ganglia using
c-Fos expression. As shown in the Fig. 4d, neuronal
activity was highly increased in the CPu (Fig. 4da, 4dd)
and the GP (Fig. 4db, 4de) after MPTP treatment. How-
ever, MPTP treatment did not cause any increase in the
neuronal activity of STN (Fig. 4df ) compared to saline
treatment. These data suggest that the dynamic net-
works and neuronal activity within the basal ganglia, i.e.,
CPu, GP, and STN are abnormally modified after acute
MPTP treatment although further electrophysiological
experiments are necessary to demonstrate more clearly
the effect of MPTP on neuronal activities. Taken to-
gether, we found that acute MPTP treatment can induce
astroglial and microglial activation in STN and result in
neuronal dysfunction of basal ganglia in parallel to the
degeneration of SNpc dopaminergic neurons. Finally, we
examined whether or not acute MPTP treatment in-
duces astrocytic and microglial activation, and degener-
ation of dopaminergic neurons (Fig. 5), or neuronal
activity changes (Fig. 6) in the spinal cord. Acute MPTP
treatment changed the number or shape of neither as-
trocytes (Fig. 5a, b) nor microglia (Fig. 5c, d) in the
lumbar spinal cord compared to saline treatment. In
addition, there was no difference in TH-immunopositive
neurons (Fig. 5e, f ), MAP2 immunoreactivities (Fig. 6a, b),
and the expression of c-Fos in both spinal dorsal and
ventral horns (Fig. 6c, d, e) after acute MPTP treatment
suggesting that there is no degeneration of neurons in-
cluding dopaminergic neurons in acute MPTP model.
Therefore, these results suggest a central mechanism of
painful sensation related to PD and provide a basis for
substantial beneficial effects of STN deep brain stimula-
tion (DBS) (STN-DBS) in PD patients [10, 11].
Discussion
In this study, we showed that depletion of dopaminergic
neurons in the nigrostriatal pathway by acute intraperito-
neal injection of MPTP induced an alteration of behav-
ioral responses to mechanical and thermal stimulation. In
the rotarod test, which is widely used to confirm motor
deficits in rodent PD models [21], MPTP-treated mice ex-
hibited clear motor deficits. However, the distance moved
and basal anxiety level in the OFT was not affected by
MPTP administration, which was consistent with other
studies [14, 22]. To exclude explorative behavior in the
open field, we additionally performed the round chamber
test and confirmed that mice displayed locomotor dys-
function after MPTP injection.
MPTP-treated mice exhibited more sensitive nociceptive
behavior when mechanical stimulation was introduced.
MPTP-treated mice showed shorter paw withdrawal
latencies in the automated von Frey test compared to
saline-treated counterparts (Fig. 3a). This indicated
Fig. 4 (See legend on next page.)
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Fig. 4 Change of astrocytes and neurons in the basal ganglia of MPTP-administered mice. a Change of astrocyte activation and neuron in the
STN after MPTP treatment. GFAP-immunoreactivity was increased in the STN after MPTP treatment (Ae-h) compared to saline treatment (Aa-d), whereas
there is no difference in NeuN-immunoreactivity between two groups (scale bars = 100 μm) (n = 4 per group). b Change of astrocyte activation and
neuron in the GP after MPTP treatment. There were no differences in GFAP- and NeuN-immunoreactivity in the GP after MPTP treatment (Be-h)
compared to saline treatment (Ba-d) (scale bars = 50 μm) (n = 4 per group). c Change of microglial activity in the CPu, the GP, and the STN after MPTP
treatment. The Iba1 expression (red arrows) as a marker for microglial activity was increased in the CPu (Cd) and the STN (Cf), but not in the GP (Ce)
after MPTP treatment (Cg) compared with saline treatment (Ca, Cb, and Cc, respectively) (scale bars = 100 μm) (n= 5 per group, p < 0.001, CPu; p < 0.05,
STN, unpaired t-test). d Change of neuronal activity in the caudate-putamen, the GP, and the STN after MPTP treatment. The c-Fos expression as a
marker for neuronal activity was remarkably increased in the CPu (Dd) and the GP (De), but not in the STN (Df) after MPTP treatment (Dg) compared
with saline treatment group (Da, Db, and Dc, respectively) (scale bars = 100 μm) (n = 4 per group, p < 0.0001, CPu; p < 0.01, GP, unpaired t-test). CP,
cerebral peduncle; CPu, caudate-putamen; GP, globus pallidus; i.c., internal capsule; Opt, optic tract; STN, subthalamic nucleus
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by MPTP injection. A similar effect was observed with
the administration of 6-OHDA in rats, which increased
the nociceptive response to mechanical stimulation
compared to controls [5]. MPTP-treated mice also
exhibited a lower nociceptive threshold for thermal
stimuli compared to saline-treated mice, suggesting
modified behavioral response to thermal stimulationsFig. 5 Quantitative analysis of astroglial and microglial activation to MPTP tre
astrocytes in the dorsal horn of the lumbar spinal cord between saline- and M
showed no difference in the number of astrocytes in the spinal cord (n = 4 pe
in the dorsal and ventral horn of the lumbar spinal cord between saline- and M
showed no difference in the number of microglial cells in the spinal cord (n= 4
(red arrows) in the ventral horn of the lumbar spinal cord between saline- and M
showed no difference in the number of TH-positive neurons in the spinal cordby intraperitoneal MPTP administration (Fig. 3b, c).
Although we did not investigate alterations in the re-
sponse latency to thermal stimuli during the PD induc-
tion phase in this mouse, our results revealed the
effects of MPTP on thermal nociceptive thresholds
might show up after PD induction, which was consist-
ent with a previous study describing the long-term ef-
fects of MPTP [21].atment in the spinal cord. a Comparison of GFAP-immunopositive
PTP-treated mice (scale bars = 200 μm). b Saline- and MPTP-treated mice
r group, unpaired t-test). c Comparison of Iba1-immunopositive microglia
PTP-treated mice (scale bars = 200 μm). d Saline- and MPTP-treated mice
per group, unpaired t-test). e Comparison of TH-immunopositive neurons
PTP-treated mice (scale bars = 200 μm). f Saline- and MPTP-treated mice
(n = 4 per group, unpaired t-test)
Fig. 6 Change of neurons in the spinal cord of MPTP-administered mice. a Comparison of MAP2-immunopositive spinal neurons in the dorsal
and ventral horn of the lumbosacral spinal cord between saline- and MPTP-treated mice (scale bars = 200 μm). Upper and lower rectangles
represent dorsal and ventral horns, respectively. Higher magnification images of these dorsal and ventral horns showed in lower two panels
(scale bars = 200 μm). b MPTP-treated PD model mice did not exhibit any neuronal changes in either the dorsal or ventral horn of the lumbosacral
spinal cord (n = 4 per group, unpaired t-test). c Comparison of c-Fos immunolabelled neurons in the dorsal and ventral horn of lumbar spinal cord
between saline- and MPTP-treated mice (scale bars = 200 μm). Higher magnification images of these dorsal and ventral horns showed in lower two
panels, respectively (scale bars = 200 m). d and (e) MPTP-treated PD model mice did not show any differences in neuronal activity in either the dorsal
or ventral horn of the lumbar spinal cord (n = 4 per group, unpaired t-test), respectively
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remains unknown and there is no existing therapeutic
tool for pain. In the present study, we found that the
degenerative loss of dopaminergic neurons in SNpc in-
duced astrogliosis and microglial activation related to
inflammation and neuronal dysfunction in the basal
ganglia including CPu, GP, and STN, which has a dopa-
minergic connection from the SNpc, but not in the
spinal dorsal horn (known to be a key site for pain pro-
cessing). In other studies, 6-OHDA injection into the
striatum generated a moderate increase in astrocyte ac-
tivation in the GP [17], and an MPTP-treated chronic
PD mouse model showed a loss of motor neurons andactivation of astrocytes in the spinal cord [23]. The dis-
crepancy between these results and our findings is
likely due to the protocol used to induce the PD model:
(1) MPTP vs. 6-OHDA, and (2) MPTP-chronic vs.
MPTP-acute models. Although the mechanisms under-
lying remote local activation of astrocytes and microglia
after MPTP injection remains uncertain, the local in-
flammatory responses in the STN in response to SNpc
dopaminergic neuronal loss might be the key point to
be discussed in the view of pain mechanisms and pain
therapeutics such as deep brain stimulation (DBS) of
STN in PD. Indeed, recent clinical data demonstrated
the therapeutic effect of STN-DBS on pain in PD
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lief is still a matter of debate. In addition, it is already
well known that abnormal overactivity of GP neurons
by glutamatergic input from STN involves in the motor
symptoms of PD and STN-DBS can control the over-
activity of STN-GP pathways leading to slow progres-
sion of motor symptoms in PD [24].
The basal ganglia have roles not only in attention,
cognition, and stress [25–27], but also in movement
and pain, as well-indicated in PD patients [28, 29]. Be-
sides the GP and STN, the striatum comprised of
caudate-putamen is the largest of four major nuclei in
the basal ganglia. The dopaminergic system in the stri-
atum has been implicated in pain. Inhibition or activa-
tion of striatal dopamine D2 receptors is related to
nociceptive responses [4]. Human studies also support
the function of dopamine D2 receptors in pain [30]. In
line with the studies mentioned above, here we found
that acute MPTP administration significantly reduced
dopaminergic fibers and highly increased the neuronal
activity in the striatum, especially in dorsal striatum.
Moreover, MPTP-induced dopaminergic neuronal de-
generation lowered nociceptive thresholds in mice.
These results suggest that the dopaminergic nigrostria-
tal pathway also has a role in inhibiting basal mechanical
and thermal nociception. However, the nigrostriatal path-
way or SNpc-STN neuronal circuitry may not be the only
pathway to modulate nociceptive thresholds to mechan-
ical and thermal stimuli leading to pain suppression. The
dopaminergic system in the spinal cord also influences
motor function as well as nociception, and dopamine D2
and D3 receptors in the spinal cord play a role in anti-
nociception [31] leading to descending inhibition [32].
On the other hand, although it has been reported that
MPTP induces lesions selectively of dopaminergic
neurons [33], intraperitoneal administration of MPTP
can induce the depletion of dopaminergic neurons in
the forebrain as well as spinal cord [34] affecting de-
scending facilitation of pain. Increased expression of
D2 receptor in anterior cingulate cortex is correlated
with nociceptive pain in neuropathic pain [35] and
inflammatory nociception results in the increase of D2
receptors in the insular cortex [36]. In addition, inflam-
matory responses or dopamine D1 receptor of spinal
cord can mediate pro-nociceptive actions [37]. In our
study, however, we did not find any changes in
astroglial/microglial activation, the number of TH-
immunopositive neurons, and neuronal activity after
acute MPTP treatment. Taken together, we suggest that
pain symptoms of PD induced by acute MPTP adminis-
tration could be related to supraspinal mechanism in
the modulation of pain rather than spinal mechanism.
Thus, apart from inflammatory activation and neuronal
activity using c-Fos expression, further studies aboutalterations of basal nociceptive thresholds induced by
depletion of dopaminergic neurons at the spinal cord
and cortical level are clearly needed.
In summary, the present results confirm that intra-
peritoneal acute MPTP administration in mice induces
degeneration of dopaminergic neurons and fibers in the
striatum and the SNpc, increased neuronal activity in
the striatum and GP, and inflammatory activity in the
STN, which are all involved in nociception. Although
motor deficits were detected in MPTP-treated group,
their exploration level in the OFT was normal and even
their pain behavioral response latencies to mechanical
and thermal stimuli were significantly shorter than the
saline-treated group. Taken together, MPTP-induced
mouse PD model can be used to investigate pain symp-
toms and central pain processing mechanisms related
to PD.
Conclusions
The abnormal nociceptive threshold and pain perception
which is the most common non-motor symptoms could
be related to dysfunctional neural circuitry induced by
inflammatory responses such as astrogliosis and neural
activity within basal ganglia including striatum, globus
pallidus, subthalamic nucleus, and substantia nigra in
acute Parkinson’s disease.
Materials and methods
Animals and drug administration
Experiments were performed with 8–9 weeks old male
C57BL/6J mice (19 ~ 24 g) because female mice have
much higher sensitivity than male mice to noxious stimuli
due to the biological factors including sex hormones’
effect [38]. Mice were group housed and kept under con-
ditions of a 12 h light/dark cycle with an ad libitum food
and water supply. All experiments were approved by Seoul
National University or Kyungpook National University
Institutional Animal Care and Use Committees.
MPTP treatment
Mice were injected intraperitoneally (i.p.) with MPTP
(20 mg/kg, Sigma, M0896) or sterile saline solution (four
times at 2 h intervals) [3].
L-DOPA treatment
L-DOPA (Sigma, D1507) was dissolved in sterile saline.
Mice were injected subcutaneously with L-DOPA
(40 mg/kg) or sterile saline solution. All tests were per-
formed at 45 min post-injection [39].
Behavioral tests
Mice were held in their home cage for 30 min before the
behavioral tests.
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The rotarod training was performed at the same time
for 10 min during five consecutive days: on the first day,
mice were placed on the rotating rod at 4 rpm for
5 min. Every 30 s, the rod speed was increased by 1 rpm
up to 15 rpm, and then maintained this speed for one
minute. On the second day, a 4 rpm speed was used for
1.5 min. The rod speed was increase by 1 rpm every 30 s
until it reached 20 rpm, which was maintained for
10 min. On the third, fourth, and fifth days, the latencies
of falling off rod were measured three times with linear
increase of rod speed from 4 rpm up to 40 rpm for
5 min and averaged. The actual test was performed after
the drug treatment. The test protocol was the same with
the last three days of the training protocol.
Open field test (OFT)
Each mouse was placed in an open field arena (40 cm x
40 cm x 40 cm) made of white acrylic and video moni-
tored from above for 5 min. Total distance moved and
total time spent in three zones (10 cm x 10 cm, 20 cm x
20 cm for center and 40 cm x 40 cm excluding the center
area for the peripheral zone) were calculated using
ETHOVISION 9.0 software (Noldus).
Round chamber test
The mice were placed in a round chamber (15 cm diam-
eter, 10 cm height) for 10 min and video-recorded from
above. The video recording files were analyzed using
ETHOVISION 9.0 software (Noldus) [40, 41].
Dynamic plantar aesthesiometer
To measure the mechanical nociceptive threshold, mice
were habituated in a Dynamic Plantar Aesthesiometer
(Ugo Basil, 37,450) for 30 min (or more) until they stabi-
lized. Ascending force was given to the hind paw of the
mice until paw withdrawal occurred. The force increased
from 0 to 5 g over a 10 s period (0.5 g/s), and 5 g force
was maintained for an additional 10 s [42].
Hot plate test
The thermal nociceptive responses were measured by
placing mice on a hot plate (Harvard Apparatus) having
a constant temperature (48 °C or 53 °C). The latency of
flinching, licking, or jumping behavior was recorded. In
order to prevent tissue damage at 53 °C, a cut-off time
of 20 s was employed [43].
Tail-flick test
The thermal nociceptive responses of the tail were mea-
sured by tail-flick apparatus (LE7106 Tail-flick Meter).
Laser stimulation was applied to the dorsal surface of
the tail until the tail was flicked. The beam light inten-
sity was adjusted to have 4–6 s of tail flick latencies forthe average baseline. The latency time was measured
three times with 3 min intervals. The light was focused
on different points of the tail (1 cm apart) in each trial.
Immunohistochemistry
Mice were anesthetized by ketamine injection and trans-
cardially perfused with 25 ml of phosphate buffered
saline (PBS), followed by 25 ml of 4 % paraformaldehyde
(PFA) dissolve in PBS. Brains were removed and kept in
5 ml of 4 % PFA in PBS overnight at 4 °C, and then sub-
merged for 48 h at 4 °C in 30 % sucrose dissolved in
PBS. Brains were frozen in frozen section compound
(Leica #3801480) and serial coronal sections were made
on a cryostat at 30 μm thickness. Twenty-four brain
slices including caudate-putamen and globus pallidus
(GP), forty-two slices of SNpc, and twelve slices of subtha-
lamic nucleus (STN) were obtained and conserved in 50 %
glycerol (in PBS). Free-floating four striatum/GP brain
slices, seven SNpc slices, and two STN slices from each
mouse were rinsed three times for 5 min in PBS at room
temperature (RT) and incubated in blocking solution (2 %
goat serum, 1 % bovine serum albumin (BSA) and 0.5 %
Triton X-100, in PBS) for 1 h. The sections were incubated
with primary antibodies against tyrosine hydroxylase (TH)
(1:1000, abcam, ab76442), glial fibrillary acidic protein
(GFAP) (1:1000, Dako, USA), Iba1 (1:1000, abcam, ab5076),
NeuN (1:1000, Millipore, USA), and c-Fos (1:1000, Santa
Cruz, SC-52, USA) in blocking solution overnight at 4 °C,
and then secondary antibodies, anti-goat or anti-rabbit
Alexa Fluor 488 or 594 IgG (1:300, Invitrogen) for 2 h at
RT. The relative intensity level of TH-immunoreactive fi-
bers in the striatum was measured using ImageJ program.
The TH-immunoreactive neurons in the SNpc were
counted by ImageJ program with Point Picker plugin.
For immunohistochemistry of spinal neurons, astro-
cytes, and microglia, the same procedures mentioned
above were applied. Mice were anesthetized by ketamine
at 30 min after the last injection of MPTP. Lumbar and
sacral spinal cords were dissected out after transcardinal
perfusion with fixatives and 48 spinal cord slices were
obtained. Spinal neurons and astrocytes in six lumbar-
sacral slices from each mouse were labeled with primary
antibodies against microtubule-associated protein 2
(MAP2), GFAP, Iba1, and c-Fos, respectively. The c-Fos
expression analysis was done as described in Yu et al.
[44]. The relative intensity of immunopositive cells for
MAP2, GFAP, Iba1, and c-Fos in the spinal cord was
measured using ImageJ program. The immunoreactive
neurons and astrocytes were counted by ImageJ program
with Point Picker from four among the six slices.
Western blotting
Coronal brain slices (400 μm thickness) including
striatum or SNpc were prepared with a vibratome
Park et al. Molecular Pain  (2015) 11:28 Page 11 of 12(Intracel Ltd), and homogenized in RIPA buffer comprising
(in mM): TriCl 50 at pH 7.6; NaCl 150; EDTA 1; DTT 1;
NP-40 1 %; SDS 0.1 %; sodium deoxycholate 0.5 %. Im-
munoblotting was performed using tyrosine hydroxylase
(TH) (1:1000; Millipore), actin (1:10,000; Invitrogen) and
then goat anti-rabbit IgG (1:5000; Cell Signaling). Bands on
nitrocellulose (NC) membrane were visualized using a
Chemiluminescent HRP Substrate kit (Millipore) and Che-
miDoc XRS+ (721BR02655, Bio-Rad). ImageJ program was
used to quantify the band intensity.
Data analysis
All data were plotted on graphs and statistical analyzed
using the GraphPad Prism 5.01 program.
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